Who can use Cotellic(Cobimetinib)?

Cotellic is indicated for BRAF-mutant unresectable or metastatic melanoma in combination with vemurafenib and as monotherapy for histiocytic neoplasms.

Therapeutic Indications for Cobimetinib

Cobimetinib, a MEK inhibitor, is approved for two distinct adult populations: first, in combination with vemurafenib for treating unresectable or metastatic melanoma harboring a BRAF V600E or V600K mutation, confirmed via FDA-approved testing. Second, it is indicated as a single agent for the treatment of various histiocytic neoplasms, including Erdheim-Chester disease and Langerhans cell histiocytosis.